Colgate-Palmolive stock holds near $91 as Q2 2026 sales edge higher
Published on 08/26/2026 at 18:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Colgate-Palmolive (ISIN US1941621039) stock is trading in the low-$90s as of late August 2026, with investors weighing modest second-quarter 2026 sales growth against softer profit and a valuation that still prices in continued earnings resilience. As of August 25, 2026, the shares closed at $91.33 on the New York Stock Exchange, providing a reference point for recent trading levels. For investors, the gap between the current price and the prevailing analyst target range has become a key talking point.
Q2 2026 results show higher sales but lower profit
According to a recent earnings summary covering the June quarter, Colgate-Palmolive reported net sales of $5.361 billion in the second quarter of 2026, compared with $5.11 billion in the same period of the prior year, indicating year-over-year top-line growth. The same report notes that operating profit reached $1.016 billion in Q2 2026, down from $1.08 billion a year earlier, highlighting margin pressure despite the higher sales base. Net income attributable to the company declined as well, to $693 million in Q2 2026 from $743 million in the second quarter of 2025, underscoring that earnings contracted even as revenue increased.
This combination of rising revenue and lower operating and net profit suggests that Colgate-Palmolive faced higher costs or an unfavorable mix in the quarter, a dynamic that can weigh on valuation if investors start questioning the sustainability of profit growth. At the same time, the modest sales increase indicates that core demand in oral care, home care, and personal care categories remained resilient through the first half of 2026 despite competitive pressures. For long-term shareholders, the key question is whether management can translate this sales momentum back into expanding margins in subsequent quarters.
Market pricing and analyst consensus in late August 2026
Recent market data show Colgate-Palmolive stock changing hands at $91.33 at the close of trading on August 25, 2026, with the shares indicated to open at $91.27 in subsequent trading. One detailed stock analysis page notes that the shares traded at $92.11 in intraday activity on August 26, 2026, representing a modest gain versus the prior close and placing the stock within a tight price band around the low-$90s. A local-market listing overview also cites a price of $90.10 for the shares in a separate snapshot, further reinforcing that recent trading has clustered close to the $90 mark.
Consensus data compiled in late August 2026 indicate that analysts maintain a moderate buy rating on Colgate-Palmolive, with an average price target of $99.00. That target sits roughly $7.67 above the $91.33 close on August 25, 2026, implying potential upside of a bit more than 8 percent if the company executes in line with expectations. Several institutional-trading reports highlight that the stock recently opened at $91.27, which helps anchor the valuation discussion by tying the consensus target to a very specific recent price point. The difference between the current quote cluster around $91 and the $99 target range illustrates that the market is not pricing in an extreme growth scenario, but it does assume continued steady earnings and cash generation.
An additional fundamental perspective is provided by a valuation framework that estimates a fair value, or GF Value, of $95.08 for Colgate-Palmolive shares. With the stock trading at $91.33 per share in that analysis, the methodology characterizes the stock as undervalued by 3.9 percent relative to this fair-value estimate. This modest discount aligns with the moderate buy consensus and suggests that, as of late August 2026, the shares are viewed as fairly valued to slightly undervalued rather than significantly mispriced. For income-focused investors, this type of valuation context provides a reference point for weighing the company’s dividend and earnings outlook.
Institutional flows highlight steady demand
Several recent filings and alerts describe active trading by large institutional investors in Colgate-Palmolive shares, providing further color on how professional money managers view the stock following the Q2 2026 report. One filing summary notes that a major asset manager sold 142,646 shares of Colgate-Palmolive, a move that modestly reduced its exposure while still keeping the stock in its portfolios. Another report highlights that a different institutional investor purchased 60,041 shares, adding to its position and signaling continued confidence in the company’s ability to deliver long-term returns.
A separate disclosure states that another large asset manager lowered its holdings in Colgate-Palmolive, aligning with the broader pattern of portfolio adjustments rather than wholesale exits. These mixed but generally moderate transactions suggest that institutional investors are fine-tuning their exposure rather than abandoning or aggressively accumulating the stock. Taken together with the moderate buy analyst consensus and the slight discount to fair value, the pattern of buys and sells indicates that the stock is seen as a steady consumer staples holding rather than a high-beta trading vehicle.
From a sector perspective, Colgate-Palmolive’s positioning in household and personal care means that its stock often behaves defensively, especially in volatile macroeconomic environments. The Q2 2026 numbers, with net sales of $5.361 billion and net income of $693 million, illustrate that the company continues to generate substantial cash flow even when margins compress. For institutional investors balancing growth and stability, this combination of defensiveness and consistent earnings helps explain why the shares remain widely held despite short-term profit headwinds.
Colgate oral care products anchor the brand
Colgate-Palmolive’s most recognizable products include its Colgate-branded toothpastes and toothbrushes, which remain a core driver of sales and brand recognition globally. In many markets, Colgate maintains leading share in toothpaste, and the company’s innovation pipeline spans whitening products, sensitivity relief formulations, and children’s offerings. This wide product range helps support the $5.361 billion in net sales reported for the second quarter of 2026, as oral care continues to account for a significant portion of revenue.
Beyond oral care, the company’s portfolio extends into home care, personal care, and pet nutrition, but the Colgate toothpaste brand often serves as the entry point for consumers. The strength of this flagship brand gives Colgate-Palmolive pricing power and shelf presence in both developed and emerging markets, which is critical when managing cost pressures that can squeeze operating profit, as seen in the Q2 2026 decline from $1.08 billion to $1.016 billion year over year. By continuing to invest in product differentiation and marketing, the company aims to translate its brand equity into sustainable earnings growth over time.
Colgate-Palmolive stock and recent price levels
Colgate-Palmolive stock is listed on the New York Stock Exchange under the ticker symbol CL, and recent trading data highlight a narrow band of prices around $90 to $92 as of late August 2026. One summary page cites a last price of $92.11 as of August 26, 2026, 11:44 a.m. Eastern Time, representing a gain of 0.85 percent for the session and indicating that the stock has been edging higher intraday. Another market overview shows the shares at $91.72 at 12:34 p.m. Eastern Time on August 26, 2026, with the price down 0.90 percent at that moment, underscoring that intraday moves can fluctuate within a relatively tight range.
Given the August 25, 2026, close of $91.33 and the cited intraday levels of $92.11 and $91.72 on August 26, 2026, the stock currently trades just a few dollars below the average analyst target of $99.00. This places the shares in a zone where modest changes in sentiment, earnings expectations, or macroeconomic conditions could push them closer to or further from the consensus target. For investors, the key reference points are the Q2 2026 revenue figure of $5.361 billion, the net income of $693 million, and the implied valuation that sees the stock priced at a slight discount to a $95.08 fair-value estimate as of the latest analysis.
Read more
Colgate-Palmolive stock quote and analysis
Colgate toothpaste as a flagship product
Within Colgate-Palmolive’s broad portfolio, Colgate Total toothpaste stands out as a flagship product that embodies the company’s focus on oral health and innovation. This line offers multi-benefit formulations that target cavities, plaque, gingivitis, and enamel strength, supporting the company’s leadership position in the category. The sustained demand for such products feeds directly into the company’s quarterly net sales performance, including the $5.361 billion reported for the second quarter of 2026.
By leveraging global distribution networks and strong relationships with retailers, Colgate-Palmolive ensures that its oral care products remain highly visible and accessible to consumers. This visibility reinforces brand loyalty and helps stabilize revenue even when economic conditions become more challenging. As seen in the Q2 2026 results, revenue growth can still occur in tandem with margin pressure, underscoring the importance of high-volume, high-recognition products like Colgate Total in maintaining sales momentum.
Colgate-Palmolive stock in a consumer staples context
In the broader consumer staples landscape, Colgate-Palmolive stock often serves as a benchmark for investors seeking exposure to defensive names with reliable cash flows. The Q2 2026 net sales of $5.361 billion and net income of $693 million illustrate the scale of the company’s operations and its capacity to generate earnings even in periods of cost inflation. When combined with an average analyst price target of $99.00 and a fair-value estimate of $95.08 against a current price band around $91, the stock presents a profile of moderate upside potential tied to stable fundamentals.
As of August 26, 2026, the shares’ trading range between $90.10 and $92.11 in various intraday snapshots underscores the relative calm around the name compared with more volatile sectors. For many portfolios, Colgate-Palmolive functions as a ballast, contributing steady dividends and earnings with lower price swings. The recent Q2 2026 figures, showing revenue growth but lower profit compared with the prior year, will be a key reference in upcoming quarters as investors assess whether margin pressures ease and earnings re-accelerate.
Fact box
Company: Colgate-Palmolive Company
ISIN: US1941621039
Ticker: CL
Exchange: New York Stock Exchange (NYSE)
Price (as of August 25, 2026, 4:00 p.m. ET): $91.33 USD
Sector / Industry: Consumer staples / Household and personal care
